Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | Torkinib |
Synonyms | |
Therapy Description |
Torkinib (PP242) inhibits mTOR signaling through mTORC1/2, thereby preventing cell proliferation (PMID: 19209957). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Torkinib | PP242 | mTOR Inhibitor 51 | Torkinib (PP242) inhibits mTOR signaling through mTORC1/2, thereby preventing cell proliferation (PMID: 19209957). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
PTEN loss | breast cancer | resistant | Torkinib | Preclinical - Cell culture | Actionable | In a preclinical study, breast cancer cell lines with PTEN loss demonstrated resistance to Torkinib (PP242) in culture (PMID: 21358673). | 21358673 |
PIK3CA act mut PTEN wild-type | breast cancer | sensitive | Torkinib | Preclinical - Cell culture | Actionable | In a preclinical study, 9/9 breast cancer cell lines harboring a PIK3CA activating mutation and PTEN wild-type demonstrated sensitivity to treatment with Torkinib (PP242) in culture, resulting in decreased cell viability (PMID: 21358673). | 21358673 |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|